Category - News

Developments

Eyenovia posts positive results from second MicroStat Phase 3 trial

Eyenovia (NASDAQ:EYEN) reported positive results from its second Phase 3 study, MIST-2, evaluating the safety and efficacy of its MicroStat fixed-combination formulation for the treatment of pharmacologic mydriasis, or...

February 25, 2019

Markets

HCW starts Pulse Biosciences at buy; PT $27

H.C. Wainwright launched coverage of Pulse Biosciences (NASDAQ:PLSE) with a “buy” rating and price target of $27. The stock closed at $18.23 on Feb. 22. Analyst Swayampakula Ramakanth writes that his recommendation is...

February 25, 2019

Markets

Stifel ups Obalon Therapeutics to buy; PT to $3 from $2.50

Stifel upgraded Obalon Therapeutics (NASDAQ:OBLN) to “buy” from “hold” and raised its price target to $3 from $2.50, saying the company is entering 2019 with “multiple incremental/critical adoption drivers now in...

February 25, 2019

Markets

Analysts downgrade Diplomat Pharmacy on 10-K filing delay

Analysts for William Blair and SVB Leerink downgraded Diplomat Pharmacy (NYSE:DPLO) after the company delayed reporting fourth-quarter results and filing its 10-K. The stock fell $7.59, or 56%, to $5.87 in heavier than...

February 25, 2019

Developments

ImmunoPrecise Antibodies receives subcontract for rabbit monoclonal antibodies

ImmunoPrecise Antibodies (TSXV:IPA; OTC:IPATF) has received a five-year subcontract from Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the NCI, to discover and...

February 21, 2019

Markets

HCW starts BioTime at buy; PT $4

H.C. Wainwright launched coverage of BioTime (NYSE American:BTX) with a “buy” rating and $4 price target. The stock closed at $1.15 on Feb. 20. Analyst Joseph Pantginis writes that BioTime was originally focused on...

February 21, 2019

Executive Moves

Roth names Tony Butler as head of biotech research

Roth Capital Partners appointed Charles “Tony” Butler as a managing director, senior research analyst and head of biotechnology research, and a partner.

February 21, 2019

Developments

Clearlake Capital-backed symplr to acquire API Healthcare

symplr, a leading healthcare governance, risk and compliance (GRC) software-as-a-service (SaaS) platform, backed by Clearlake Capital Group, has agreed to acquire API Healthcare, a leading provider of healthcare human...

February 20, 2019

Markets

Roth starts Arcturus Therapeutics at buy; PT $14

Roth Capital Partners launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $14 price target. The stock closed at $4.84 on Feb. 19. “Arcturus is a hidden gem in a sea of RNA medicines...

February 20, 2019

Developments

BioSig reports successful first-in-human use of PURE EP system

BioSig Technologies (NASDAQ:BSGM) reported that it successfully conducted first patient cases using its PURE EP system at the Texas Cardiac Arrhythmia Institute in Austin, Tex. PURE EP is an FDA-approved cardiac signal...

February 20, 2019

Category - News

Subscribe